MX2011012632A - Inhibidores de actividad de cinasa tipo pirimidina. - Google Patents

Inhibidores de actividad de cinasa tipo pirimidina.

Info

Publication number
MX2011012632A
MX2011012632A MX2011012632A MX2011012632A MX2011012632A MX 2011012632 A MX2011012632 A MX 2011012632A MX 2011012632 A MX2011012632 A MX 2011012632A MX 2011012632 A MX2011012632 A MX 2011012632A MX 2011012632 A MX2011012632 A MX 2011012632A
Authority
MX
Mexico
Prior art keywords
sup
kinase activity
compounds
pyrimidine inhibitors
pyrimidine
Prior art date
Application number
MX2011012632A
Other languages
English (en)
Inventor
Scott A Erickson
George S Sheppard
Jieyi Wang
Steve D Fidanze
Gary T Wang
Randy L Bell
Robert A Mantei
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2011012632A publication Critical patent/MX2011012632A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

En la presente solicitud se describen compuestos de la fórmula (I) o sales o solvatos farmacéuticamente aceptables de los mismos, en la cual L1, R2, R3, R4, R5, y m se definen en la descripción. También se describen métodos para elaborar dichos compuestos, y composiciones que comprenden dichos compuestos los cuales son útiles para inhibir cinasas tales como IGF-IR.
MX2011012632A 2009-05-27 2010-05-26 Inhibidores de actividad de cinasa tipo pirimidina. MX2011012632A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18154509P 2009-05-27 2009-05-27
PCT/US2010/036187 WO2010138578A1 (en) 2009-05-27 2010-05-26 Pyrimidine inhibitors of kinase activity

Publications (1)

Publication Number Publication Date
MX2011012632A true MX2011012632A (es) 2012-03-06

Family

ID=42340681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012632A MX2011012632A (es) 2009-05-27 2010-05-26 Inhibidores de actividad de cinasa tipo pirimidina.

Country Status (7)

Country Link
US (1) US8486933B2 (es)
EP (1) EP2435422B1 (es)
JP (1) JP2012528177A (es)
CN (1) CN102459236B (es)
CA (1) CA2763633A1 (es)
MX (1) MX2011012632A (es)
WO (1) WO2010138578A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3330293T3 (pl) * 2008-11-07 2020-02-28 Amgen Research (Munich) Gmbh Leczenie ostrej białaczki limfoblastycznej wieku dziecięcego za pomocą biswoistych przeciwciał przeciwko cd3xcd19
ME02363B (me) 2008-11-07 2016-06-20 Amgen Res Munich Gmbh Liječenje akutne limfoblastične leukemije
AU2013341271A1 (en) * 2012-11-07 2015-05-14 Novartis Ag Combination therapy
AR096654A1 (es) * 2013-06-20 2016-01-27 Ab Science Derivados de benzimidazol como inhibidores selectivos de proteína quinasa
CN105622520A (zh) * 2014-08-25 2016-06-01 上海博悦生物科技有限公司 一种治疗非小细胞肺癌药物色瑞替尼(Ceritinib)的新中间体及其制备方法
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
CZ2015613A3 (cs) 2015-09-09 2017-03-22 Zentiva, K.S. Způsob přípravy Ceritinibu
CN108602802B (zh) * 2016-07-26 2020-01-21 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN109516977B (zh) * 2019-01-23 2020-01-10 长治学院 一种苯胺嘧啶/喹啉杂合物、制备方法及医药用途
CN111004221B (zh) * 2019-12-13 2021-02-02 长治学院 一种嘧啶/苯并咪唑杂合物、制备方法及医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511378A (ja) * 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US7338959B2 (en) * 2002-03-01 2008-03-04 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1841760B1 (en) * 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2006129100A1 (en) 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
EP2091918B1 (en) * 2006-12-08 2014-08-27 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0815979A2 (pt) * 2007-08-28 2017-06-13 Irm Llc compostos e composições com inibidores de quinase, bem como uso dos mesmos

Also Published As

Publication number Publication date
CN102459236B (zh) 2014-10-29
CN102459236A (zh) 2012-05-16
WO2010138578A1 (en) 2010-12-02
CA2763633A1 (en) 2010-12-02
JP2012528177A (ja) 2012-11-12
EP2435422B1 (en) 2014-12-17
US8486933B2 (en) 2013-07-16
US20100305112A1 (en) 2010-12-02
EP2435422A1 (en) 2012-04-04

Similar Documents

Publication Publication Date Title
MX2011012632A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2011012629A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2011013325A (es) 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
MX2012013197A (es) Inhibidores de indazol de cinasa.
MX2011012631A (es) Inhibidores de actividad de cinasa tipo pirimidina.
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
MY148634A (en) Pyridazinone derivatives
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
MX2009010595A (es) Derivados de pirrolopirimidina.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
GEP20125564B (en) Pyrimidine derivatives as kinase inhibitors
MX2010002336A (es) Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
MX2009013077A (es) Derivados dde benzoxazolona.
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
MY154898A (en) P70 s6 kinase inhibitors
MY146989A (en) Kinase inhibitors
TN2010000131A1 (en) Polo-like kinase inhibitors
MX2009007302A (es) Derivados de purina.
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration